{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:45:01Z","timestamp":1789825501921,"version":"4.0.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.neuropharm.2025.110673","type":"journal-article","created":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T06:33:46Z","timestamp":1757140426000},"page":"110673","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Cytoprotective effects of Gymnemic Acid 1 in cellular models of neurodegeneration"],"prefix":"10.1016","volume":"280","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7415-2711","authenticated-orcid":false,"given":"Sneha Sujitkumar","family":"Kapse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2678-1178","authenticated-orcid":false,"given":"Mattia M.","family":"Migliore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.neuropharm.2025.110673_bib1","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-024-03165-6","article-title":"Western diets and chronic diseases","volume":"30","author":"Adolph","year":"2024","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110673_bib2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1471-4159.2004.02190.x","article-title":"Neurochemical and behavioural changes in zebrafish Danio rerio after systemic administration of 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: effects of MPTP and 6-OHDA on zebrafish brain","volume":"88","author":"Anichtchik","year":"2004","journal-title":"J. Neurochem."},{"issue":"10103","key":"10.1016\/j.neuropharm.2025.110673_bib3","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110673_bib4","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with Parkinson's disease","volume":"123","author":"Aviles-Olmos","year":"2013","journal-title":"J. Clin. Investig."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110673_bib6","doi-asserted-by":"crossref","first-page":"174","DOI":"10.2174\/1871527319666200518102130","article-title":"Interlink between insulin resistance and neurodegeneration with an update on current therapeutic approaches","volume":"19","author":"Bhattamisra","year":"2020","journal-title":"CNS Neurol. Disord.: Drug Targets"},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110673_bib7","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.3390\/cells10051236","article-title":"Insulin resistance and diabetes mellitus in Alzheimer's disease","volume":"10","author":"Burillo","year":"2021","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110673_bib8","article-title":"Brain gene expression of a sporadic (icv-STZ mouse) and a familial mouse model (3xTg-AD mouse) of Alzheimer's disease","volume":"7","author":"Chen","year":"2012","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.neuropharm.2025.110673_bib9","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/j.cmet.2024.09.003","article-title":"GLP-1 programs the neurovascular landscape","volume":"36","author":"Chen","year":"2024","journal-title":"Cell Metab."},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110673_bib10","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028035","article-title":"Pathology of neurodegenerative diseases","volume":"9","author":"Dugger","year":"2017","journal-title":"Cold Spring Harbor Perspect. Biol."},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110673_bib11","doi-asserted-by":"crossref","first-page":"10956","DOI":"10.3390\/molecules190810956","article-title":"Triterpenoids from Gymnema sylvestre and their pharmacological activities","volume":"19","author":"Fabio","year":"2014","journal-title":"Molecules"},{"issue":"17","key":"10.1016\/j.neuropharm.2025.110673_bib12","doi-asserted-by":"crossref","first-page":"6275","DOI":"10.3390\/ijms21176275","article-title":"Pathophysiology of type 2 diabetes mellitus","volume":"21","author":"Galicia-Garcia","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2025.110673_bib13","series-title":"Combat Neurodegenerative Diseases Crisis with Technology and Public Policy","author":"Giani","year":"2022"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110673_bib14","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1007\/s12035-015-9132-3","article-title":"Intracerebroventricular streptozotocin injections as a model of Alzheimer's disease: in search of a relevant mechanism","volume":"53","author":"Grieb","year":"2016","journal-title":"Mol. Neurobiol."},{"issue":"20","key":"10.1016\/j.neuropharm.2025.110673_bib15","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.3390\/nu14204298","article-title":"Targeting Alzheimer's disease: the critical crosstalk between the liver and brain","volume":"14","author":"Huang","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.neuropharm.2025.110673_bib16","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1475-2891-12-116","article-title":"Major food sources of calories, added sugars, and saturated fat and their contribution to essential nutrient intakes in the U.S. diet: data from the national health and nutrition examination survey (2003-2006)","volume":"12","author":"Huth","year":"2013","journal-title":"Nutr. J."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110673_bib17","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000350435","article-title":"Neurodegeneration in streptozotocin-induced diabetic rats is attenuated by treatment with resveratrol","volume":"98","author":"Jing","year":"2013","journal-title":"Neuroendocrinology"},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110673_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25073812","article-title":"GLP-1 receptor agonists: A new treatment in Parkinson\u2019s disease","volume":"25","author":"Kalinderi","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"106550","key":"10.1016\/j.neuropharm.2025.110673_bib18","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: implications for neurodegenerative disease treatment","volume":"186","author":"Kopp","year":"2022","journal-title":"Pharmacol. Res."},{"issue":"2 Pt 1","key":"10.1016\/j.neuropharm.2025.110673_bib19","doi-asserted-by":"crossref","first-page":"C319","DOI":"10.1152\/ajpcell.1994.266.2.C319","article-title":"The insulin receptor: structure, function, and signaling","volume":"266","author":"Lee","year":"1994","journal-title":"Am. J. Physiol."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110673_bib20","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1073\/pnas.0806720106","article-title":"GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and parkinsonism","volume":"106","author":"Li","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2025.110673_bib21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.peptides.2018.07.001","article-title":"GLP-1 receptor agonists stimulate ANGPTL8 production through the PI3K\/Akt pathway in a GLP-1 receptor-dependent manner","volume":"106","author":"Liu","year":"2018","journal-title":"Peptides"},{"issue":"11","key":"10.1016\/j.neuropharm.2025.110673_bib22","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.3390\/cells10113164","article-title":"High-fat, western-style diet, systemic inflammation, and gut microbiota: a narrative review","volume":"10","author":"Malesza","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.neuropharm.2025.110673_bib23","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3389\/fphar.2020.00805","article-title":"Stimulation of GLP-1 receptor inhibits methylglyoxal-induced mitochondrial dysfunctions in H9c2 cardiomyoblasts: potential role of Epac\/PI3K\/Akt pathway","volume":"11","author":"Nuamnaichati","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110673_bib24","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/jsfa.6458","article-title":"A systematic review of Gymnema sylvestre in obesity and diabetes management: a systematic review ofGymnema sylvestre","volume":"94","author":"Pothuraju","year":"2014","journal-title":"J. Sci. Food Agric."},{"issue":"37","key":"10.1016\/j.neuropharm.2025.110673_bib25","doi-asserted-by":"crossref","first-page":"25711","DOI":"10.1074\/jbc.M114.560409","article-title":"Molecular mechanisms for sweet-suppressing effect of gymnemic acids","volume":"289","author":"Sanematsu","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.neuropharm.2025.110673_bib26","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.2337\/diab.43.11.1326","article-title":"STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells","volume":"43","author":"Schnedl","year":"1994","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110673_bib27","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0378-8741(90)90106-4","article-title":"Possible regeneration of the islets of langerhans in streptozotocin-diabetic rats given Gymnema sylvestre leaf extracts","volume":"30","author":"Shanmugasundaram","year":"1990","journal-title":"J. Ethnopharmacol."},{"issue":"3\u20134","key":"10.1016\/j.neuropharm.2025.110673_bib28","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF03033565","article-title":"The 6-hydroxydopamine model of Parkinson's disease","volume":"11","author":"Simola","year":"2007","journal-title":"Neurotox. Res."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110673_bib29","doi-asserted-by":"crossref","first-page":"537","DOI":"10.33549\/physiolres.930111","article-title":"The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas","volume":"50","author":"Szkudelski","year":"2001","journal-title":"Physiol. Res."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110673_bib30","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1210\/clinem\/dgaa863","article-title":"Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes","volume":"106","author":"Thomas","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.neuropharm.2025.110673_bib31","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/830285","article-title":"Phytochemical and pharmacological properties of gymnema sylvestre: an important medicinal plant","volume":"2014","author":"Tiwari","year":"2014","journal-title":"BioMed Res. Int."},{"issue":"24","key":"10.1016\/j.neuropharm.2025.110673_bib32","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.3390\/nu14245287","article-title":"The effect of a 14-Day Gymnema sylvestre intervention to reduce sugar cravings in adults","volume":"14","author":"Turner","year":"2022","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110673_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/cells13010065","article-title":"GLP1 receptor agonists-effects beyond obesity and diabetes","volume":"13","author":"Wilbon","year":"2023","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110673_bib34","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","article-title":"Hallmarks of neurodegenerative diseases","volume":"186","author":"Wilson","year":"2023","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110673_bib35","doi-asserted-by":"crossref","first-page":"9370","DOI":"10.1002\/jcp.27621","article-title":"Gymnemic acid I triggers mechanistic target of rapamycin-mediated \u03b2 cells cytoprotection through the promotion of autophagy under high glucose stress: WU et al","volume":"234","author":"Wu","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110673_bib36","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13024-017-0149-0","article-title":"The SH-SY5Y cell line in Parkinson's disease research: a systematic review","volume":"12","author":"Xicoy","year":"2017","journal-title":"Mol. Neurodegener."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110673_bib37","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Targeted Ther."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825003818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825003818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T21:19:14Z","timestamp":1768511954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390825003818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":37,"alternative-id":["S0028390825003818"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110673","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytoprotective effects of Gymnemic Acid 1 in cellular models of neurodegeneration","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110673","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110673"}}